TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study

被引：0
|
作者：
Angevin, E.
Lopez, J. A.
Pande, A.
Moldovan, C.
Shi, M.
Soria, J. C.
Wang, X.
Harzstark, A.
Saro, J.
Escudier, B.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Novartis Oncol, E Hanover, NJ USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3563
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Razak, Albiruni R. A.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
    Kessler, Elizabeth R.
    Hu, Junxiao
    Srivastava, Geetika
    Kemme, Douglas Jerome
    Iruku, Praveena
    Rana, Vishal
    Schuster, Steven Robert
    Amirault, Mali
    Callihan, Eryn
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3.
    Milowsky, M. I.
    Carlson, G. L.
    Shi, M. M.
    Urbanowitz, G.
    Zhang, Y.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Gordon, M. S.
    Stein, M.
    Shannon, P.
    Eddy, S.
    Tyler, A.
    Catlett, L.
    Hsyu, P.
    Huang, B.
    Healey, D.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3
    Milowsky, Matthew I.
    Dittrich, Christian
    Martinez, Ignacio Duran
    Jagdev, Satinder
    Millard, Frederick E.
    Sweeney, Christopher
    Bajorin, Dean F.
    Cerbone, Linda
    Dunn, Robert M.
    Sen, Paramita
    Shi, Michael
    Kay, Andrea C. M.
    Squires, Matthew
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC).
    McGregor, Bradley Alexander
    Adib, Elio
    Xie Wanling
    Stadler, Walter Michael
    Zakharia, Yousef
    Michaelson, Dror M.
    Alva, Ajjai Shivaram
    Farah, Subrina
    Nassar, Amin
    Harshman, Lauren C.
    Kwiatkowski, David J.
    McKay, Rana R.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS' SEQUENTIALLY TREATED WITH TARGETED THERAPIES (TTS)
    Procopio, G.
    Verzoni, E.
    Testa, I.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [38] RANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Motzer, R. J.
    Rini, B. I.
    McDermott, D. F.
    Redman, B.
    Kuzel, T.
    Harrison, M. R.
    Vaishampayan, U. N.
    Drabkin, H.
    George, S.
    Logan, T.
    Margolin, K.
    Plimack, E. R.
    Waxman, I.
    Lambert, A.
    Hammers, H.
    ANNALS OF ONCOLOGY, 2014, 25
  • [39] A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) - final results
    Escudier, B.
    Srinivas, S.
    Roigas, J.
    Gillessen, S.
    Harmenberg, U.
    De Mulder, P. H.
    Fountzilas, G.
    Vogelzang, N.
    Peschel, C.
    Flodgren, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 299 - 300
  • [40] A phase I study of pazopanib (P) combined with bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors
    Negrier, Sylvie
    Perol, David
    Bahleda, Rastilav
    Hollebecque, Antoine
    Chatelut, Etienne
    Boyle, Helen Jane
    Cassier, Philippe A.
    Ferlay, Celine
    Metzger, Severine
    Blanc, Ellen
    Soria, Jean-Charles
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345